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T-cell receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs) are circular DNA
segments generated in T and B cells during their maturation in the thymus and bone marrow. These circularized
DNA elements persist in the cells, are unable to replicate, and are diluted as a result of cell division, thus are
considered markers of new lymphocyte output. The quantification of TRECs and KRECs, which can be reliably
performed using singleplex or duplex real-time quantitative PCR, provides novel information in the management of
T- and B-cell immunity-related diseases. In primary immunodeficiencies, when combined with flow cytometric
analysis of T- and B-cell subpopulations, the measure of TRECs and KRECs has contributed to an improved
characterization of the diseases, to the identification of patients’ subgroups, and to the monitoring of stem cell
transplantation and enzyme replacement therapy. For the same diseases, the TREC and KREC assays, introduced in
the newborn screening program, allow early disease identification and may lead to discovery of new genetic
defects. TREC and KREC levels can also been used as a surrogate marker of lymphocyte output in acquired
immunodeficiencies. The low number of TRECs, which has in fact been extensively documented in untreated
HIV-infected subjects, has been shown to increase following antiretroviral therapy. Differently, KREC number, which
is in the normal range in these patients, has been shown to decrease following long-lasting therapy. Whether
changes of KREC levels have relevance in the biology and in the clinical aspects of primary and acquired
immunodeficiencies remains to be firmly established.
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V(D)J recombination and formation of excision circles
Thymus and bone marrow (BM) are the primary anatomic
sites for new T- and B-cell generation from undifferenti-
ated hematopoietic precursors (Figure 1). Throughout this
process, a highly heterogeneous lymphocyte repertoire is
generated allowing the resulting cells to respond to a wide
variety of antigenic stimuli [1-3]. Physiologically, T-cell
maturation in the thymus progresses through distinct* Correspondence: limberti@yahoo.it
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reproduction in any medium, provided the orstages that are phenotypically defined by the expression of
the T-cell receptor (TR) and the CD4 and CD8 co-
receptors. On the basis of a programmed expression of
distinct cell surface markers and of ordered gene re-
arrangements, thymocytes undergo different maturation
steps before reaching the end stage [4]. B-lymphocyte de-
velopment is divided into two main phases: an initial
antigen-independent phase, in which precursor B cells
mature into functional B lymphocytes in the BM, and an
antigen-dependent phase, in which the mature B-cell
compartment is maintained by regeneration, turnover and
selection processes [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 New T- and B-cell generation. A) Lymphoid progenitors migrate to the thymus, where they progressively rearrange T-cell receptor
(TR) genes. Before the rearrangements of the TR alpha (TRA) locus, the TR delta (TRD) locus, which lies within the TRA locus, must be excised by
DNA recombinations. Among them, the δREC–ψJα recombination, which occurs in about 70% of thymocytes [13], leads to the generation of a
δREC–ψJα coding joint (CJ) in the chromosome and of a δREC–ψJα signal joint (SJ) in a circle of DNA called TR excision circle (TREC). Maturing
thymocytes undergo 3–4 intrathymic divisions, in which TRECs cannot be duplicated; thus, only a fraction (about 1:8–1:16) of the originally TREC+
cells will leave the thymus as TREC+ recent-thymic emigrants (RTE) [6,13,15]. Peripheral proliferation will determine further TREC dilution. B) In the bone
marrow, progenitor B cells undergo V(D)J rearrangements of the Ig heavy chain (IGH) locus followed by those of the light chains (IGK and IGL). After
successful IGH rearrangements at the Pre-B stage, a VJ recombination on the IGK locus is initiated. If it is not productive, another recombination
between the Ig kappa deleting element or like (IGKDEL) and one of the upstream recombination signal sequences (RSS) renders the IGK allele
non-functional. In 30%-50% of cases, this occurs through the intronRSS-IGKDEL rearrangement, by which the IGKC exon and its enhancers
(iEκ, 3’Eκ) are excised, with the creation of the so-called kappa-deleting recombination excision circles (KRECs). Thus, KRECs carry an intronRSS-
IGKDEL SJ, and remain in the cells, but, as they cannot be replicated, they will be diluted during peripheral expansion of mature B cells.
Instead, an intronRSS-IGKDEL CJ is formed and stably retained in the genomic DNA [7,8,10], because, due to the enhancer loss, any further
rearrangement in the IGK locus is precluded.
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and of B-cell receptor (BcR) heavy and light chains, gen-
omic rearrangements of antigen receptor genes generate
functional receptors. This process is necessary because the
gene complexes encoding the TR and BcR components
do not contain a functional first exon, while including
multiple variable (V), diversity (D), and joining (J) genes.
In the antigen-independent differentiation phase, stepwise
rearrangements are introduced into the genome to couple
one of each segment together to form a functional first
exon. The rearrangement of the TR alpha (TRA) genes has
the peculiarity of involving the excision of delta-coding
segments that, being nestled in the TRA locus between the
TRAV and TRAJ genes, must be removed in order to allow
the generation of the TRA chain. The excised DNA is cir-
cularized due to the ligation of the blunt DNA signal ends,
thereby forming a signal joint (SJ) within the stable circular
excision products termed TR excision circles (TRECs) [6].
Therefore, TRECs are the excised DNA circles formed
during the process of TRA chain VJ recombination
(Figure 1A). In B-cell maturation, K-deleting recombinationexcision circles (KRECs) are the products of recombination
events determining the allelic and isotypic exclusion of the
Ig kappa (IGK) locus [7-9]. They are created in those B
lymphocytes that, after completing the IG heavy gene re-
arrangement, have failed to productively rearrange IGK
genes on one or both alleles [10]. In these cells, the IGK
locus becomes non-functional through the deletion of the
IGK constant gene (IGKC) resulting from the recombination
of the Ig kappa deleting element or like (IGKDEL), which is
a sequence located approximately 24 kb downstream of
the IGKC, with one of the upstream recombination signal
sequences (RSS) located either at the 3’ side of a IGK
variable gene segment (IGKV) or in the intron between
the IGK joining segments (IGKJ) and the IGKC [10].
When the IGKDEL recombines with the RSS located in
the IGKJ-IGKC intron (intronRSS), the formation of a
coding joint (CJ) precludes any further rearrangements in
the IGK locus. Thus, the CJ remains present in the genome,
whereas an intronRSS-IGKDEL SJ is formed in the portion
of DNA that is removed, thus forming the excision circle
KREC (Figure 1B) [7,8].
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Assays for quantification of TRECs and KRECs in periph-
eral blood are now performed in clinical and research la-
boratories to monitor naive T and B cells emigrating from
the thymus and BM, respectively. Although TRECs are
not markers of recent thymic emigrants by definition, be-
cause a small part remains present in peripheral blood in
the so-called “old” thymic emigrants [6,11-14], several
properties identify them as “bona fide” useful markers of
thymic output. They are stable, do not replicate upon cell
division and therefore are diluted in the progeny, do not
degrade easily over time, and are (almost) exclusively of
thymic origin, without extrathymic sources of TR re-
arrangements [6]. In particular, approximately 70% of T
cells differentiating in the thymus contain TRECs [11], be-
fore being diluted 1:8–1:16 because of intrathymic divi-
sions occurring during the last steps of maturation
[13,15]. The TREC quantitative assay, initially proposed by
Douek DC et al. [6], has been later modified in different
ways and TREC number has been evaluated in different
biological samples or calculated by different approaches,
resulting into hardly comparable results. In fact, a
more accurate TREC measurement has been obtained
when quantification was performed relative to a control
gene, such as chemokine (C-C motif) receptor 5, albumin,
or TRA constant (TRAC) gene [12,16,17]. Furthermore,
TREC content in peripheral blood has been reported
either relative to peripheral blood mononuclear cells
(PBMC), or quantified within sorted individual T-cell sub-
sets [12,18]. In addition, the quantity of TRECs has been
expressed either as absolute number of TREC mole-
cules per μg of DNA within PBMC or T lymphocytes
[16,19,20], or per 106 cells, on the basis of the theoretical
recovery of 1 μg of DNA from approximately 150,000 cells
[21,22]. Because in adults’ samples TREC calculation per
106 PBMC can lead to erroneous interpretations due to
the diluting effect of peripheral T-cell divisions, this limi-
tation has been, at least in part, overcome by expressing
TRECs per ml of blood [23,24]. Finally, in spite of the
present lack of information regarding TREC half-life [13],
several mathematical models, which have taken into con-
sideration confounders such as cell death, longevity of
naive T cells, and intracellular degradation, have been re-
cently proposed to identify the actual thymic output as a
function of the TREC number [22,24].
Scanty information are presently available regarding
the quantification of KRECs. Because the CJ remains in
the genome, whereas the SJ present in the KREC is di-
luted after each cell division, the difference between the
cycle threshold (Ct) values of the SJ and the CJ, obtained
by real-time PCR, has been initially exploited to calcu-
late the average number of divisions in a pool of B cells.
In particular, because the intronRSS-IGKDEL rearrange-
ment occurs late during BM differentiation, this measureis a good estimate of the average number of divisions
performed by mature B cells after leaving the precursor B-
cell compartment [7]. Furthermore, the frequency of B-
cells that contain an intronRSS–IGKDEL rearrangement
can be determined when a control gene is quantified to-
gether with the CJ [8]. A modified technique was used to
determine the number of developing B lymphocytes in the
BM of children with B-precursor acute lymphoblastic
leukemia treated with allogeneic human stem-cell trans-
plantation (HSCT) [25]. In this assay, KRECs were calcu-
lated by using the ΔCt method with a calibrator sample
and by correcting the quantity and quality of DNA in the
samples employing albumin as reference gene. The final
number of KRECs relative to the calibrator was expressed
as: 2Ctcalibrator-Ctsample + log2(DNAconc. calibrator/DNAconc. sample).
More recently, we modified this newly proposed KREC
assay and the widely used TREC assay by setting up a du-
plex quantitative real-time PCR that, by measuring to-
gether TRECs and KRECs, allows the quantification of
newly produced T and B lymphocytes [26,27]. The main
advantage of the combined assay is that the variability re-
lated to direct DNA quantification is eliminated by the
use of a unique standard curve obtained by diluting the
triple-insert plasmid, which contains TREC, KREC and
TRAC fragments in a 1:1:1 ratio [26]. The last serves as a
control for both the quality and quantity of genomic DNA
in the sample. Furthermore, the simultaneous quantifica-
tion of the two targets in the same reaction, results into a
containment of laboratory costs. The duplex TREC/KREC
assay is performed on DNA extracted from PBMC iso-
lated from heparinized blood using primers and probes
specific for TRECs, KRECs and TRAC. TRECs or KRECs
per 106 PBMC are calculated as the ratio between the
mean number of TRECs or KRECs and the mean copy
number of TRAC divided by 2, which is the number of
TRAC copies per cell, and multiplied by 106. This value, in
conjunction with the combined lymphocyte - monocyte
number in one ml of blood (which are the cells contained
in a PBMC preparation), is used to calculate the number
of TRECs or KRECs per ml of blood (TRECs or KRECs
per 106 PBMC) × (lymphocyte plus monocyte count in
one ml of blood)/106 [26].
TRECs and KRECs as markers of primary and acquired
immunodeficiencies
TREC level has been extensively assayed in children with
primary immunodeficiencies (PID) in whom the decreased
number and function of T and/or B cells result into sig-
nificant impairment of immunity. These rare, genetically
determined disorders, which characteristically manifest
during infancy and childhood with increased frequency of
infections caused by unusual pathogens, are often accom-
panied by immunoregulatory defects [28]. Severe com-
bined immunodeficiency (SCID), the most serious and
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cies of T- and B-cell functions and a low number of nat-
ural killer (NK) cells [29,30]. Infants with SCID develop
failure to thrive, chronic diarrhea, and infections in
the first few months of life. Graft-versus-host disease
(GVHD), caused by maternal T-cell engraftment, may
occur in these patients, who also show skin rash and
organomegaly. All infants with the typical form of SCID,
as well as those with another form of SCID, known as the
Omenn syndrome, show extremely low or undetectable
TREC levels (see Table 1, which completes and extendsTable 1 T- and B-cell immunodeficiencies in which TRECs and
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ADA: adenosine deaminase; AK2: adenylate kinase 2; AT: ataxia-telangectasia; ATM: A
molecule, gamma (CD3-TCR complex); CD40LG: CD40 ligand; CD8A: CD8A molecule;
forkhead box P3; IgAD: IgA deficiency; IL10RA: interleukin 10 receptor, alpha; IL2RA:
interleukin 7 receptor, alpha; JAK3: Janus kinase 3; KRECs: k-deleting recombination
Nijmegen breakage syndrome; nd: not done; PNP: purine nucleoside phosphorylase
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WAS: Wiskott-Aldrich syndrome; XLA: X-linked agammaglobulinemia; ZAP70: zeta-ch
↑: over the cut-off; ↓: lower than the cut-off or undetectable.the data reported by van Zelm et al.) [8,26,31-42]. Despite
the normal number of circulating T cells, abnormally low
TREC levels were also observed in patients with zeta-
chain (TCR) associated protein kinase 70kDa (ZAP70)
deficiency and with the 22q11.2 deletion syndrome, espe-
cially in those without an identifiable thymus [31,38]. In
contrast, patients with mutations in CD40 ligand,
forkhead box protein 3 (FOXP3), and interleukin 10 recep-
tor alpha chain, as well as patients with the p.R222C
mutation in the interleukin 2 receptor gamma gene, dis-
play normal TREC levels [31]. As in SCID patients, theKRECs have been evaluated
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; RAG1: recombination activating gene 1; RAG2: recombination activating gene
: severe combined immunodeficiency; TRECs: T-cell receptor excision circle;
ain (TCR) associated protein kinase 70kDa.
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ology of other PID such as CD4+ T lymphocytopenia.
In these patients, TREC levels correlated to the severity
of the T-cell immunodeficiency [43]. Finally, TREC
quantification has been used to improve our under-
standing of the T-cell abnormality that is sometimes ob-
served in common variable immunodeficiency (CVID),
although its precise role in this condition is still a mat-
ter of debate. While in fact some authors reported that
the median TREC level in these patients was signifi-
cantly higher than in healthy subjects, others found that
this number was significantly reduced, in particular in
patients characterized by a low number of switched/
memory B cells (sIgD-CD27+), by a large proportion of
CD19hiCD21lo cells, and by an increased risk of auto-
immunity and splenomegaly [41,44-46].
KREC level has been evaluated only very recently in
children with PID, and mainly in patients affected by X-
linked or non X-linked agammaglobulinemia (XLA and
non-XLA, respectively), and in those with CVID. While
XLA, the most severe form of B-cell defects, results from
a mutation in the Bruton agammaglobulinemia tyrosine
kinase (BTK) gene that causes a B-cell differentiation ar-
rest in the BM, with consequent absence of mature B cells
and serum Ig, non-XLA is characterized by hypo-
gammaglobulinemia with decreased B-cell counts in the
absence of the BTK gene mutation [47]. In both forms,
which account for about 20% of all B-cell defects, recur-
rent infections appear between 3 and 18 months of age
[48]. KREC measurement has been proposed as a poten-
tial tool for the identification of these two diseases, be-
cause B-cell maturation defects occur before IGKDEL
events, and therefore KRECs should be not produced/
detected in these patients. Indeed, a study performed by
analyzing KRECs derived from dried blood spots revealed
that no KRECs were detected in 30 XLA and 5 non-XLA
patients [40]. We employed the combined TREC/KREC
assay to measure the extent of T- and B-cell neoproduction
in CVID adult patients with no acute infections and under-
going Ig passive immunotherapy. The number of TREC+
lymphocytes, which depended on age and gender, was sig-
nificantly reduced. At the same time, KREC number was
lower than in controls, but it did not change with age and
was not influenced by the gender. Of note, 35% of CVID
patients had less KRECs/ml than the 5th percentile calcu-
lated in controls [41]. On the contrary, newborns affected
by CVID (and those with some other typical SCID, see
Table 1) displayed a number of KRECs comparable to that
of healthy newborns [34]. Very recently, Kamae et al. [42]
showed that the amount of TRECs and KRECs can be a
useful marker to assess the pathogenesis and clinical seve-
rity of CVID in distinct patients.
While the quantification of TRECs has been performed
for years and is used as a surrogate marker of thymicoutput in HIV-infected patients [6], the precise interpret-
ation of TREC data obtained in acquired immunodefi-
ciency subjects is more challenging. Indeed, it depends
heavily on the assumed fate of naive T cells, recent thymic
emigrants in particular [12,24,49], and on the different
clinical-pathological parameters of infected subjects, such
as age and plasma HIV-1 RNA. Although several studies
have shown that HIV-infected subjects have a lower num-
ber of TRECs than that found in age-matched uninfected
individuals [6,12,16,50], the TREC number is variable
among patients and overlaps with that of controls [16].
Using the TREC/KREC assay we found that the number
of TREC+ cells of patients that need antiretroviral therapy
was significantly lower not only when compared to con-
trols, but also when compared to HIV-infected patients
with a relatively conserved CD4 cell number and not re-
quiring treatment according to the current guidelines. In
this latter group, the number of KRECs was significantly
higher than that found in patients needing treatment,
but similar to that found in age-matched healthy con-
trols [51].
TREC/KREC assay for detection of neonatal primary
immunodeficiency diseases
Early recognition of SCID should be considered a
pediatric emergency, because a diagnosis before the vac-
cination programs and the onset of recurrent infections
allows lifesaving HSCT, enzyme replacement, or gene
therapy [52-60]. Similarly, early diagnosis and treatment,
including periodical intravenous Ig replacement therapy,
are essential to improve the prognosis and the quality of
life of patients with B-cell defects. However, infants with
SCID or agammaglobulinemia often appear normal at
birth, have no family history of immunodeficiency [61],
and, consequently, many of them are not identified until
life-threatening infections occur.
The demonstration that the TREC assay detects SCID
patients regardless of the underlying genetic defects [33]
and that agammaglobulinemia patients can be identified
with KREC quantification [40], suggested that the TREC
and KREC assays can be used for the detection of SCID
and agammaglobulinemia in newborn screening (NBS)
programs. This is particularly true for SCID, which satis-
fies the criteria recommended by the Secretary’s Advis-
ory Committee on Heritable Disorders in Newborns and
Children [62]. The TREC assay was the first to be modi-
fied and calibrated to allow the test to be performed on
DNA extracted from small spots of dried blood, to be
highly sensitive and specific for SCID, cost-effective, re-
producible and, therefore, amenable to be used in a
population-based screening [63]. Pilot studies of NBS for
SCID, integrated with diagnosis and management guide-
lines, have been performed in some U.S. states [61]. Ac-
cordingly, in 2008, Wisconsin became the first state to
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followed, in February 2009, by Massachusetts [32,64] and,
later, by New York, Navajo Nation, California, Puerto Rico
and Louisiana [65]. By using in-house modifications of the
TREC assay (with the exception of California, where a
TREC assay kit under development by a company was
used), these pilot studies identified, among the 961,925
newborns screened, several cases of T-cell deficits, 14 of
which resulted to be SCID at the confirmatory tests, 6
SCID variants, and 40 T-cell lymphopenia not related to
SCID [32,35,63-65]. All infants with SCID identified in
Wisconsin and Massachusetts have undergone transplant-
ation or enzyme replacement therapy and are all alive
[36,37]. More recently, also the TREC/KREC assay was
modified, making it suitable to be performed on a single
Guthrie card punch. This assay has been validated in a co-
hort of 2,560 NBS cards from healthy neonates and used
to identify patients with SCID, XLA, ataxia-telangiectasia,
and Nijmegen-breakage-syndrome [34]. The early diagno-
sis of children with XLA is expected to significantly im-
prove their quality of life and contribute to a reduction of
health care costs. Indeed, because their clinical phenotype
is less severe than that in SCID, the risk of undiagnosed
disease in their first years of life in absence of a screening
program would foster the development of more severe
organ damage.
Conclusively, considering that the TREC measurement
is performed at the relatively low cost of approximately $
5.50 per assay [37], that the inclusion of KREC detection
in the TREC assay barely increases the costs, and that
SCID and agammaglobulinemia have a combined esti-
mated incidence of 1:30,000-1:50,000 births, a single assay
capable of screening for both conditions should further
improve the cost-effectiveness of the NBS for PID. The
importance of introducing PID in NBS programs has been
underlined by the guidelines very recently proposed by
Borte et al. [66].
Quantification of TRECs and KRECs for therapy
monitoring of primary and acquired immunodeficiencies
Patients with SCID have a very short life-expectancy if
they are not promptly treated with HLA-identical or
HLA-haploidentical HSCT [67,68], which frequently re-
sults into a durable engraftment of all hematopoietic cell
lineages that leads to a restoration of immunological func-
tions in the absence of GVHD [68,69]. Therefore, the suc-
cess of HSCT mainly depends on the rate of cellular
immune reconstitution [70-75]. However, while innate im-
munity shows a full phenotypic and functional recovery
within a month from transplantation [76], the recovery of
T cells can be significantly delayed, even in comparison to
that of B cells, which can occur within 6–9 months
(although a fully functional reconstitution encompassing
the synthesis of all Ig isotypes may require up to 2 years)[76-80]. Therefore, due to the impairment of both T- and
B-cell functions, HSCT recipients are more prone to in-
fections and relapse of malignancies [81,82], and the risk
of developing these complications notably correlates with
the recovery of CD4+ T cells [83]. Because it is known
that, in these patients, the appearance of TRECs is the
most predictive indicator for long-term T-cell reconstitu-
tion [84], a frequent monitoring of the T-cell immunity
and TREC number after HSCT can help identify those pa-
tients who will eventually fail to be properly reconstituted,
thus requiring additional therapies that could be more
timely initiated. The use of the TREC assay may be also
relevant to verify the outcome of unconditioned trans-
plantations with matched sibling and family donors. In
these cases, which are highly successful in terms of sur-
vival outcome, the assay may be informative in detecting a
long-term thymopoiesis, or to establish whether the T-cell
reconstitution is due to an engraftment of mature T cells
that will ultimately be exhausted, thus leading to a long-
term T-cell deficiency [83]. Indeed, a low TREC number
has been found after unconditioned procedures, indicating
the occurrence of only a limited prethymic progenitor-cell
engraftment. Therefore, in these transplantations, the long
term T-cell immunity is likely to be sustained by a pool of
mature T cells [85]. Finally, the progressive decline of
thymopoiesis observed after HSCT has been attributed to
a number of factors. These include: a defective thymic
microenvironment, which is derived from pre-existing al-
terations or GVHD-induced damages; the lack of an ad-
equate reservoir of healthy donor stem cells (associated
with the lack of conditioning); an insufficient HSC dose;
or the recipient’s age [83,86,87].
The long-term (functional) immune recovery was par-
ticularly difficult to assess in Adenosine deaminase
(ADA)-SCID patients. Treatments of these patients have
included HSCT from an HLA-identical sibling donor
without conditioning regimen, when available [88], en-
zyme replacement therapy [89], transplantation with unre-
lated donor cells [88], and gene therapy [90,91]. Using the
TREC/KREC assay, we conducted a detailed evaluation of
T- and B-cell reconstitution in patients with broadly over-
lapping immunologic parameters, treated with HSCT or
with polyethylene glycol-conjugated (PEG)-ADA. We
found that the TREC level rose in both groups, but then
quickly declined and persisted at low levels in the PEG-
ADA group. The B-cell generation, studied both by B-cell
subset phenotyping and KREC quantification, was more
often impaired in the PEG-ADA group, and homeostatic
proliferation could only partly compensate the decreased
BM output [27].
TRECs/KRECs were also measured in patients with
other PID (SCID T-B-NK+, SCID T-B-NK-, SCID T-B+NK+,
SCID T-B+NK-, X-linked hyper IgM, Wiskott-Aldrich syn-
drome and familial hemophagocytic lymphohistiocytosis)
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ranging from 12 to 79 months. These children were het-
erogeneous with respect to sex, immunodeficiency type,
graft donor, age of the donors and recipients of HSCT,
type of conditioning, and occurrence and grade of GVHD.
We found that the post-transplantation increase of TRECs
and KRECs could be either strictly associated or independ-
ent of each other, and it was followed by the normalization
of the T-cell repertoire and Ig production. Some patients
showed a sharp, but transitory increase in new lymphocyte
output which declined later on; in other patients, the
TREC and KREC number remained very low for the entire
period of surveillance [26].
An early output of B and T lymphocytes from the
production and maturation sites, which is indicative of
successful clinical outcome, was demonstrated, using a
similar approach, also in transplanted SCID patients with
a deficient recombination-activating gene 2 [92].
The TREC assay was also extensively used to evaluate
the immune reconstitution in HIV-infected patients
treated with antiviral therapy [6,93-96]. Common know-
ledge is that thymic immune reconstitution of HIV-
infected patients is more successful in children than in
adults, suggesting that increased thymic output could play,
at least in the formers, a predominant role in immune re-
covery [97]. TREC number increases in both virological
responder and non-responder children, indicating that the
persistence of viremia during therapy does not impair the
increase in thymic function and the subsequent output of
naive cells [98]. In adult patients with HIV-related lymph-
oma highly responder to antiretroviral therapy, the ana-
lysis of the kinetics and the extent of T-cell reconstitution
before and after HSCT demonstrated that the very low
level of TRECs before transplantation significantly in-
creased following treatment [99], due to an extent of im-
mune recovery close to that observed in transplanted
HIV-negative patients with lymphoma [100]. Similarly,
TREC monitoring in HIV-infected patients, long-term
treated with low-doses of recombinant human growth
hormone therapy, showed a recovery of thymopoiesis, as
confirmed also by thymic index, density and area quantifi-
cation [101]. Only few data are available on the number of
KRECs in treated HIV-infected patients. One year of
therapy did not modify the KREC number, while the long-
lasting treatment (6 years) resulted in a significant de-
crease in new B-cell release from the BM [51]. However,
due to the scarcity of available data, the usefulness of
KREC quantification in these patients remains to be firmly
established.
Limitations of the use TRECs and KRECs as immunological
markers of immunodeficiency
Because TRECs and KRECs are not produced if matur-
ation of T cells and B cells ceases at early steps, they arediluted out after cell division, they can persist in old
thymic emigrant cells, and they disappear after cell death,
caution is warranted in interpreting their number in the
clinical setting. Therefore, even though expressing the
amount of TRECs or KRECs per ml of blood overcomes
the issue of peripheral dilution [24,102], this measurement
alone cannot still be considered a direct clinical marker of
immune disease. Indeed, TRECs can be decreased in sub-
jects that are not immunodeficient, such as premature ba-
bies and Down syndrome patients [103,104]. Therefore, it
must be also emphasized that TREC/KREC determination
is only the first-tier assay, that must be followed by appro-
priate second-tier assays defining the disease (if any) that
results in the low TREC/KREC values.
Conclusions
The increasing laboratory and clinical evidences reported
in this review, which extends and completes the recent
one by van Zelm et al. [8], indicate that the quantification
of TRECs and KRECs can be very informative in the man-
agement of patients with primary and acquired immuno-
deficiencies. It appeared that it is technically feasible to
introduce the TREC/KREC assay into routine laboratory
practice both for NBS and for a more critical monitoring
of the rate of T- and B-cell immune reconstitution follow-
ing HSCT and antiretroviral therapy.
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